Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.46 per share for the quarter. Catalyst Pharmaceuticals has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The business had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX traded down $0.21 during mid-day trading on Wednesday, reaching $21.56. 564,373 shares of the company's stock were exchanged, compared to its average volume of 1,191,295. The firm has a market capitalization of $2.55 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. Catalyst Pharmaceuticals has a one year low of $11.89 and a one year high of $22.20. The business's fifty day simple moving average is $20.43 and its two-hundred day simple moving average is $17.71.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. HC Wainwright boosted their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Finally, Truist Financial lifted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $29.50.

Insiders Place Their Bets

In other news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares of the company's stock, valued at approximately $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Carmen Jeffrey Del sold 36,058 shares of the company's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the sale, the insider now directly owns 12,369 shares of the company's stock, valued at approximately $227,836.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.